Targeting the AMPK pathway for the treatment of Type 2 diabetes. by Viollet, Benoît et al.
Targeting the AMPK pathway for the treatment of
Type 2 diabetes.
Benoˆıt Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie He´brard, Chloe´
Amouyal, Re´mi Mounier, Marc Foretz, Fabrizio Andreelli
To cite this version:
Benoˆıt Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie He´brard, Chloe´ Amouyal, et al..
Targeting the AMPK pathway for the treatment of Type 2 diabetes.. Frontiers in bioscience :
a journal and virtual library, 2009, 14, pp.3380-400. <inserm-00367501>
HAL Id: inserm-00367501
http://www.hal.inserm.fr/inserm-00367501
Submitted on 11 Mar 2009
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Figure 3. AMPK and the regulation of skeletal muscle metabolism.
Proposed model for the role of AMPK in the regulation of lipid and glucose
metabolism in skeletal muscle. AMPK activity may be increased by an
altered energy nucleotide or by hormonal action. This activation of AMPK
may result in an increase in glucose transport as well as an increase in fatty
acid oxidation. ACC, acetyl-CoA carboxylase; AMPK, AMP-activated
protein kinase; AS160, Akt substrate of 160kDa; CPT1-α, carnitine
palmitoyl transferase-1; Glut4, glucose tranporter 4; MCD, malonyl-CoA
decarboxylase; PGC1α, PPARγ co-activator 1α; LCACoA, Long Chain
acyl CoAs.
Figure 4. AMPK and the regulation of hepatic metabolism. Activation of
AMPK leads to the inhibition of cholesterol synthesis by the phopshorylation
of HMG-CoA reductase. By inhibiting ACC and activating MCD, AMPK
increases fatty acid oxidation via the regulation of malonyl CoA levels,
which is both a critical precursor for biosynthesis of fatty acids and a potent
inhibitor of CPT-1, the shuttle that controls the transfer of LCACoA into the
mitochondria. AMPK inhibits hepatic glucose production via the
phosphorylation of TORC2 and inhibition gene expression for key
gluconeogenic enzymes, G6Pase and PEPCK, and for the transcriptional co-
activator PGC-1α. ACC, acetyl-CoA carboxylase; AMPK, AMP-activated
protein kinase; CPT1-α, carnitine palmitoyl transferase-1; G6Pase, glucose-
6-phosphatase; LCACoA, Long Chain acyl CoAs; MCD, malonyl-CoA
decarboxylase; PEPCK, phosphoenolpyruvate carboxykinase; PGC1α,
PPARγ co-activator 1α; TORC2, transducer of regulated CREB activity 2.
